VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells

Mark A. Currier, Francis K. Eshun, Allyson Sholl, Artur Chernoguz, Kelly Crawford, Senad Divanovic, Louis Boon, William F. Goins, Jason S. Frischer, Margaret H. Collins, Jennifer L. Leddon, William H. Baird, Amy Haseley, Keri A. Streby, Pin Yi Wang, Brett W. Hendrickson, Rolf A. Brekken, Balveen Kaur, David Hildeman, Timothy P. Cripe

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Understanding the host response to oncolytic viruses is important to maximize their antitumor efficacy. Despite robust cytotoxicity and high virus production of an oncolytic herpes simplex virus (oHSV) in cultured human sarcoma cells, intratumoral (ITu) virus injection resulted in only mild antitumor effects in some xenograft models, prompting us to characterize the host inflammatory response. Virotherapy induced an acute neutrophilic infiltrate, a relative decrease of ITu macrophages, and a myeloid cell-dependent upregulation of host-derived vascular endothelial growth factor (VEGF). Anti-VEGF antibodies, bevacizumab and r84, the latter of which binds VEGF and selectively inhibits binding to VEGF receptor-2 (VEGFR2) but not VEGFR1, enhanced the antitumor effects of virotherapy, in part due to decreased angiogenesis but not increased virus production. Neither antibody affected neutrophilic infiltration but both partially mitigated virus-induced depletion of macrophages. Enhancement of virotherapy-mediated antitumor effects by anti-VEGF antibodies could largely be recapitulated by systemic depletion of CD11b + cells. These data suggest the combined effect of oHSV virotherapy and anti-VEGF antibodies is in part due to modulation of a host inflammatory reaction to virus. Our data provide strong preclinical support for combined oHSV and anti-VEGF antibody therapy and suggest that understanding and counteracting the innate host response may help enable the full antitumor potential of oncolytic virotherapy.

Original languageEnglish (US)
Pages (from-to)1014-1023
Number of pages10
JournalMolecular Therapy
Volume21
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Oncolytic Virotherapy
Myeloid Cells
Oncolytic Viruses
Vascular Endothelial Growth Factor A
Viruses
Simplexvirus
Antibodies
Neoplasms
Macrophages
Vascular Endothelial Growth Factor Receptor-2
Heterografts
Sarcoma
Up-Regulation
Injections

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Currier, M. A., Eshun, F. K., Sholl, A., Chernoguz, A., Crawford, K., Divanovic, S., ... Cripe, T. P. (2013). VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. Molecular Therapy, 21(5), 1014-1023. https://doi.org/10.1038/mt.2013.39

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. / Currier, Mark A.; Eshun, Francis K.; Sholl, Allyson; Chernoguz, Artur; Crawford, Kelly; Divanovic, Senad; Boon, Louis; Goins, William F.; Frischer, Jason S.; Collins, Margaret H.; Leddon, Jennifer L.; Baird, William H.; Haseley, Amy; Streby, Keri A.; Wang, Pin Yi; Hendrickson, Brett W.; Brekken, Rolf A.; Kaur, Balveen; Hildeman, David; Cripe, Timothy P.

In: Molecular Therapy, Vol. 21, No. 5, 05.2013, p. 1014-1023.

Research output: Contribution to journalArticle

Currier, MA, Eshun, FK, Sholl, A, Chernoguz, A, Crawford, K, Divanovic, S, Boon, L, Goins, WF, Frischer, JS, Collins, MH, Leddon, JL, Baird, WH, Haseley, A, Streby, KA, Wang, PY, Hendrickson, BW, Brekken, RA, Kaur, B, Hildeman, D & Cripe, TP 2013, 'VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells', Molecular Therapy, vol. 21, no. 5, pp. 1014-1023. https://doi.org/10.1038/mt.2013.39
Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S et al. VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. Molecular Therapy. 2013 May;21(5):1014-1023. https://doi.org/10.1038/mt.2013.39
Currier, Mark A. ; Eshun, Francis K. ; Sholl, Allyson ; Chernoguz, Artur ; Crawford, Kelly ; Divanovic, Senad ; Boon, Louis ; Goins, William F. ; Frischer, Jason S. ; Collins, Margaret H. ; Leddon, Jennifer L. ; Baird, William H. ; Haseley, Amy ; Streby, Keri A. ; Wang, Pin Yi ; Hendrickson, Brett W. ; Brekken, Rolf A. ; Kaur, Balveen ; Hildeman, David ; Cripe, Timothy P. / VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. In: Molecular Therapy. 2013 ; Vol. 21, No. 5. pp. 1014-1023.
@article{6fba53f346c240f7b04ed634d4a751c7,
title = "VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells",
abstract = "Understanding the host response to oncolytic viruses is important to maximize their antitumor efficacy. Despite robust cytotoxicity and high virus production of an oncolytic herpes simplex virus (oHSV) in cultured human sarcoma cells, intratumoral (ITu) virus injection resulted in only mild antitumor effects in some xenograft models, prompting us to characterize the host inflammatory response. Virotherapy induced an acute neutrophilic infiltrate, a relative decrease of ITu macrophages, and a myeloid cell-dependent upregulation of host-derived vascular endothelial growth factor (VEGF). Anti-VEGF antibodies, bevacizumab and r84, the latter of which binds VEGF and selectively inhibits binding to VEGF receptor-2 (VEGFR2) but not VEGFR1, enhanced the antitumor effects of virotherapy, in part due to decreased angiogenesis but not increased virus production. Neither antibody affected neutrophilic infiltration but both partially mitigated virus-induced depletion of macrophages. Enhancement of virotherapy-mediated antitumor effects by anti-VEGF antibodies could largely be recapitulated by systemic depletion of CD11b + cells. These data suggest the combined effect of oHSV virotherapy and anti-VEGF antibodies is in part due to modulation of a host inflammatory reaction to virus. Our data provide strong preclinical support for combined oHSV and anti-VEGF antibody therapy and suggest that understanding and counteracting the innate host response may help enable the full antitumor potential of oncolytic virotherapy.",
author = "Currier, {Mark A.} and Eshun, {Francis K.} and Allyson Sholl and Artur Chernoguz and Kelly Crawford and Senad Divanovic and Louis Boon and Goins, {William F.} and Frischer, {Jason S.} and Collins, {Margaret H.} and Leddon, {Jennifer L.} and Baird, {William H.} and Amy Haseley and Streby, {Keri A.} and Wang, {Pin Yi} and Hendrickson, {Brett W.} and Brekken, {Rolf A.} and Balveen Kaur and David Hildeman and Cripe, {Timothy P.}",
year = "2013",
month = "5",
doi = "10.1038/mt.2013.39",
language = "English (US)",
volume = "21",
pages = "1014--1023",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells

AU - Currier, Mark A.

AU - Eshun, Francis K.

AU - Sholl, Allyson

AU - Chernoguz, Artur

AU - Crawford, Kelly

AU - Divanovic, Senad

AU - Boon, Louis

AU - Goins, William F.

AU - Frischer, Jason S.

AU - Collins, Margaret H.

AU - Leddon, Jennifer L.

AU - Baird, William H.

AU - Haseley, Amy

AU - Streby, Keri A.

AU - Wang, Pin Yi

AU - Hendrickson, Brett W.

AU - Brekken, Rolf A.

AU - Kaur, Balveen

AU - Hildeman, David

AU - Cripe, Timothy P.

PY - 2013/5

Y1 - 2013/5

N2 - Understanding the host response to oncolytic viruses is important to maximize their antitumor efficacy. Despite robust cytotoxicity and high virus production of an oncolytic herpes simplex virus (oHSV) in cultured human sarcoma cells, intratumoral (ITu) virus injection resulted in only mild antitumor effects in some xenograft models, prompting us to characterize the host inflammatory response. Virotherapy induced an acute neutrophilic infiltrate, a relative decrease of ITu macrophages, and a myeloid cell-dependent upregulation of host-derived vascular endothelial growth factor (VEGF). Anti-VEGF antibodies, bevacizumab and r84, the latter of which binds VEGF and selectively inhibits binding to VEGF receptor-2 (VEGFR2) but not VEGFR1, enhanced the antitumor effects of virotherapy, in part due to decreased angiogenesis but not increased virus production. Neither antibody affected neutrophilic infiltration but both partially mitigated virus-induced depletion of macrophages. Enhancement of virotherapy-mediated antitumor effects by anti-VEGF antibodies could largely be recapitulated by systemic depletion of CD11b + cells. These data suggest the combined effect of oHSV virotherapy and anti-VEGF antibodies is in part due to modulation of a host inflammatory reaction to virus. Our data provide strong preclinical support for combined oHSV and anti-VEGF antibody therapy and suggest that understanding and counteracting the innate host response may help enable the full antitumor potential of oncolytic virotherapy.

AB - Understanding the host response to oncolytic viruses is important to maximize their antitumor efficacy. Despite robust cytotoxicity and high virus production of an oncolytic herpes simplex virus (oHSV) in cultured human sarcoma cells, intratumoral (ITu) virus injection resulted in only mild antitumor effects in some xenograft models, prompting us to characterize the host inflammatory response. Virotherapy induced an acute neutrophilic infiltrate, a relative decrease of ITu macrophages, and a myeloid cell-dependent upregulation of host-derived vascular endothelial growth factor (VEGF). Anti-VEGF antibodies, bevacizumab and r84, the latter of which binds VEGF and selectively inhibits binding to VEGF receptor-2 (VEGFR2) but not VEGFR1, enhanced the antitumor effects of virotherapy, in part due to decreased angiogenesis but not increased virus production. Neither antibody affected neutrophilic infiltration but both partially mitigated virus-induced depletion of macrophages. Enhancement of virotherapy-mediated antitumor effects by anti-VEGF antibodies could largely be recapitulated by systemic depletion of CD11b + cells. These data suggest the combined effect of oHSV virotherapy and anti-VEGF antibodies is in part due to modulation of a host inflammatory reaction to virus. Our data provide strong preclinical support for combined oHSV and anti-VEGF antibody therapy and suggest that understanding and counteracting the innate host response may help enable the full antitumor potential of oncolytic virotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84877024720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877024720&partnerID=8YFLogxK

U2 - 10.1038/mt.2013.39

DO - 10.1038/mt.2013.39

M3 - Article

C2 - 23481323

AN - SCOPUS:84877024720

VL - 21

SP - 1014

EP - 1023

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -